Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$524M |
| 2 |
Meta Platforms (Facebook)
META
|
+$458M |
| 3 |
Otis Worldwide
OTIS
|
+$345M |
| 4 |
T-Mobile US
TMUS
|
+$307M |
| 5 |
AbbVie
ABBV
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$878M |
| 2 |
RTN
Raytheon Company
RTN
|
+$537M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$435M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
Accenture
ACN
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.72% |
| 2 | Healthcare | 14.52% |
| 3 | Financials | 12.98% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3426
Cocrystal Pharma
COCP
$11.3M
| $400K | ﹤0.01% |
21,979
+18,489
| +530% | +$227K |
|
3427
Marchex
MCHX
$76.2M
| $400K | ﹤0.01% |
253,640
-230,885
| -48% | -$349K |
|
3428
Twin Disc
TWIN
$329M
| $399K | ﹤0.01% |
72,114
-61,126
| -46% | -$355K |
|
|
SELF
3429
Global Self Storage
SELF
$58.3M
| $398K | ﹤0.01% |
101,782
| – | – |
|
|
NMRD
3430
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
| $397K | ﹤0.01% |
+42,945
| New | +$306K |
|
3431
Amtech Systems
ASYS
$268M
| $396K | ﹤0.01% |
81,461
| – | – |
|
|
CLLS
3432
Cellectis
CLLS
$277M
| $396K | ﹤0.01% |
22,299
-3,394
| -13% | -$51.7K |
|
3433
Clarivate
CLVT
$1.27B
| $394K | ﹤0.01% |
+17,674
| New | +$399K |
|
|
SYBX
3434
DELISTED
Synlogic
SYBX
| $394K | ﹤0.01% |
12,971
-5,791
| -31% | -$185K |
|
3435
EyePoint Inc
EYPT
$1.03B
| $393K | ﹤0.01% |
51,980
-37,378
| -42% | -$322K |
|
|
SOHU
3436
Sohu.com
SOHU
$362M
| $393K | ﹤0.01% |
42,723
+10,602
| +33% | +$82.7K |
|
3437
Corvus Pharmaceuticals
CRVS
$1.12B
| $392K | ﹤0.01% |
144,362
+5,446
| +4% | +$16.1K |
|
3438
DiaMedica Therapeutics
DMAC
$342M
| $390K | ﹤0.01% |
56,412
-1,112
| -2% | -$4.96K |
|
3439
SEACOR Marine Holdings
SMHI
$256M
| $388K | ﹤0.01% |
152,493
-117,080
| -43% | -$334K |
|
3440
STRATTEC Security
STRT
$367M
| $388K | ﹤0.01% |
24,344
| – | – |
|
|
CBL
3441
DELISTED
CBL& Associates Properties, Inc.
CBL
| $388K | ﹤0.01% |
1,426,832
-1,812,752
| -56% | -$481K |
|
|
GNCA
3442
DELISTED
Genocea Biosciences, Inc.
GNCA
| $388K | ﹤0.01% |
169,001
+18,036
| +12% | +$41.5K |
|
|
HZN
3443
DELISTED
Horizon Global Corporation
HZN
| $385K | ﹤0.01% |
175,350
| – | – |
|
|
AIM
3444
AIM ImmunoTech
AIM
$7.03M
| $383K | ﹤0.01% |
+1,549
| New | +$376K |
|
|
LUMO
3445
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $382K | ﹤0.01% |
23,192
+681
| +3% | +$8.11K |
|
|
SY
3446
So-Young International
SY
$185M
| $381K | ﹤0.01% |
28,082
+14,201
| +102% | +$150K |
|
3447
vTv Therapeutics
VTVT
$127M
| $379K | ﹤0.01% |
4,219
+1,583
| +60% | +$156K |
|
|
ALPN
3448
DELISTED
Alpine Immune Sciences Inc
ALPN
| $376K | ﹤0.01% |
38,774
+1,338
| +4% | +$5.79K |
|
|
LYRA
3449
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $375K | ﹤0.01% |
+663
| New | +$485K |
|
3450
WPP
WPP
$4.36B
| $371K | ﹤0.01% |
+9,506
| New | +$354K |
|
Similar funds
Geode Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Geode Capital Management held 4,219 positions worth $467B, up 22% from $384B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geode Capital Management's Q2 2020 filing shows 118 new, 2,550 increased, 1,055 reduced and 119 closed positions. Its largest new stake was Otis Worldwide: 6,650,358 shares worth $377M. The largest sale was Allergan plc, an estimated $878M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2020 buy was Otis Worldwide: 6,650,358 shares worth $377M.
- Geode Capital Management added most to Amazon in Q2 2020, an estimated $524M increase.
- Geode Capital Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $435M.
- Geode Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $878M.
- Geode Capital Management's ten largest holdings make up 23% of its $467B portfolio in Q2 2020.
- Geode Capital Management opened 118 new positions and closed 119 in Q2 2020.
- Geode Capital Management's portfolio value rose 22% quarter-over-quarter to $467B.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.